PubMed Health⌕ Search

PubMed · 159712

Perioral dermatitis.

Abstract

Forty-three patients with perioral dermatitis are described. In seven patients, this eruption was associated with the use of hydrocortisone butyrate (Locoid) alone, and this topical steroid can no longer be recommended unreservedly for use on the face. In fifteen other patients, medication was undertaken without medical advice. The time may have come to print on tubes of potent local steroids warnings about the hazards of long-term use on the face without medical advice. Drug companies and pharmacists could also help by asking patients to discard any partially-used tubes of ointment and an expiry date stamped prominently on the tubes rather than on the cardboard container may help. Continuing medical education is obviously still required to prevent a minority of family doctors prescribing wrongly for their patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Cotterill. 1979. Perioral dermatitis.. https://doi.org/10.1111/j.1365-2133.1979.tb05617.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Poly(butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil.

Poly(butylcyanoacrylate) nanoparticles (PBCN) as a drug carrier of 5-fluorouracil (5FU) intended for topical treatment of skin lesia were investigated. The presence of 5FU (as saline solution, pH 10-11) in the polymerization medium affected the polymerization as well as the nanoparticle formation by influencing the initiation of the polymerization reaction. 5FU acted as an initiator in the anionic polymerization of n-butylcyanoacrylate monomer through its nucleophilic nitrogen centers. The results obtained by GPC, 1H NMR, and X-ray diffraction allude to a possible mechanism of cytostatic immobilization in the polymer matrix, with evidence for both free and bound forms of the drug.

Administration, Topical↗

A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.

Serotonin 5-HT2 receptor agonists have recently been shown to be effective in lowering intraocular pressure in nonhuman primates and represent a potential new class of antiglaucoma agents. As part of an effort to identify new selective agonists at this receptor, we have found that (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole (AL-37350A, 11) has high affinity and selectivity (>1000-fold) for the 5-HT(2) receptor relative to other 5-HT receptors. More specifically, 11 is a potent agonist at the 5-HT2A receptor (EC50 = 28.6 nM, E(max) = 103%) that is comparable to serotonin. Evaluation of 11 in conscious ocular hypertensive cynomolgus monkeys showed this compound to be efficacious in reducing intraocular pressure (13.1 mmHg, -37%). Thus, 11 is a potent full agonist with selectivity for the 5-HT2 receptor and is anticipated to serve as a useful tool in exploring the role of the 5-HT2 receptor and its effector system in controlling intraocular pressure.

Administration, Topical↗